Company announcement - No. 41 / 2016
Lyxumia ® (lixisenatide) royalty revenue of DKK 6 million / € 0.8 million in Q3 2016 from Sanofi's sales outside the U.S.
Copenhagen, 28 October 2016 - Zealand Pharma (Zealand), reports royalty revenue from Sanofi's global sales of lixisenatide (marketed as Lyxumia ® outside the U.S.) of DKK 6.1 million / € 0.8 million for the period from 1 July to 30 September 2016. For the first nine months of 2016, Zealand's royalty revenue amounted to DKK 19.0 million / € 2.6 million.
Lixisenatide is a once-daily prandial GLP-1 receptor agonist for the treatment of patients with type 2 diabetes and was invented by Zealand, with global development and commercialization rights licensed to Sanofi. Lixisenatide is marketed under the brand name Lyxumia ® in over 45 countries and was approved in the U.S. under the brand name Adlyxin TM in July 2016.
Sanofi has also developed iGlarLixi, a fixed-ratio combination of lixisenatide and insulin glargine 100 units/mL (Lantus ® ), which is under regulatory review in both the U.S. and Europe. A regulatory decision is expected in November 2016 in the U.S. and in Q1 2017 in Europe.
For further information, please contact:
Britt Meelby Jensen,
President and Chief Executive Officer
Tel: +45 51 67 61 28, email: firstname.lastname@example.org
Senior Vice President, Chief Financial Officer
Tel: +45 31 53 79 73 , email: email@example.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn and a pipeline of proprietary product candidates, which primarily target specialty diseases with significant unmet needs.
The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analog for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Lyxumia ® outside the United States and approved as Adlyxin TM in the United States. Lixisenatide has been developed in a fixed-ratio combination with Lantus ® (insulin glargine) which product is under regulatory review in the United States and in Europe.
Zealand's proprietary pipeline includes: Dasiglucagon * (ZP4207) as single-dose rescue treatment for acute, severe hypoglycemia (Phase II); Glepaglutide* (ZP1848) for treatment of short bowel syndrome (Phase II); Dasiglucagon* (ZP4207) multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management (in preparation for Phase II); and other earlier stage clinical and preclinical peptide therapeutics.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.
* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN)